OakChart

Immuneering Corp

IMRXHealthcare·Biotechnology·USA·Micro·NASD·Nov 11 • 10:02 AM ET

3.88+0.03 (0.65%)
2026-11-11 16:03 CET
Market cap
249.34 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-66.50 USD m
Free cash flow, TTM
-61.81 USD m
EPS diluted, TTM
-1.03
P/E
-
Compare

Price

IMRX against its 20, 50 and 200-day averages
2050200missearnings
4.005.006.007.005.1M10.2MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26IMRXclose 3.8820-day 3.7350-day 4.05200-day 4.763.88

54.3% under 8.48 on 7 Jan 2026. Last 15 sessions, 24.0% high to low

Profile

IMRX
52-week range, 10% of the way up
3.358.48

Immuneering Corp. operates as a clinical-stage oncology company, which engages in developing medicines for cancer patients. Its pipeline of drug candidates focuses on treating aspects of disease that have eluded conventional approaches, including cancer cachexia and metastasis. The company was founded by Robert J. Carpenter and Benjamin J. Zeskind in 2008 and is headquartered in Cambridge, MA.

IndexRUT
Employees37
IPOJul 30, 2021
Beta0.46
ATR, 14d0.24
Rel volume0.47
Short float26.21%
Insider own14.02%
Inst own56.14%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap250.96M
Enterprise Value109.08M
Income-66.50M
Sales0.00M
Book/sh2.60
Cash/sh2.25
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees37
IPOJul 30, 2021

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B1.49
P/C1.73
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio13.97
Current Ratio13.97
Debt/Eq0.02
LT Debt/Eq0.02
Option/ShortYes / Yes

Earnings

EPS (ttm)-1.03
EPS next Y-1.61
EPS next Q-0.40
EPS this Y2.92%
EPS next Y-30.94%
EPS next 5Y-4.62%
EPS past 3/5Y12.72% -13.77%
Sales past 3/5Y- -
EPS Y/Y TTM42.34%
Sales Y/Y TTM-
EPS Q/Q0.90%
Sales Q/Q-
EarningsOct 29 AMC
EPS/Sales Surpr.-21.31% -

Ownership

Insider Own14.02%
Insider Trans0.09%
Inst Own56.14%
Inst Trans10.80%
ROA-31.40%
ROE-33.53%
ROIC-38.72%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA203.96%
SMA50-4.37%
SMA200-18.52%
Trades-

Technical

Shs Outstand64.76M
Shs Float55.68M
Short Float26.21%
Short Ratio20.09
Short Interest14.60M
52W High8.48 -54.30%
52W Low3.35 15.67%
Volatility7.72% 6.70%
ATR (14)0.24
RSI (14)51.44
Beta0.46
Rel Volume0.47
Avg Volume726.37K
Volume44,728

Performance

Perf Week3.06%
Perf Month8.85%
Perf Quarter-25.48%
Perf Half Y-27.97%
Perf YTD-41.11%
Perf Year-42.51%
Perf 3Y-25.27%
Perf 5Y-86.70%
Perf 10Y-
Recom1.00
Target Price17.00
Prev Close3.85
Price3.88
Change %0.65%

Analyst ratings

latest 10 of 16
DateActionAnalystRating changeTargetImplied
Aug 06, 2026InitiatedHH.C. WainwrightBuy$14+261.3%
Jul 08, 2026InitiatedCCantor FitzgeraldOverweight$17+338.7%
Oct 31, 2025InitiatedLLeerink PartnersOutperform$15+287.1%
Dec 13, 2024DowngradeMMorgan StanleyEqual-Weight → Underweight
Mar 15, 2024ReiteratedNNeedhamBuy$20 → $15+287.1%
Mar 15, 2024DowngradeTTD CowenOutperform → Market Perform
Mar 15, 2024DowngradeJJefferiesBuy → Hold$16 → $3-22.6%
Dec 01, 2023InitiatedNNeedhamBuy$20+416.1%
Jun 26, 2023ResumedOOppenheimerOutperform$25+545.2%
Apr 19, 2023UpgradeMMorgan StanleyUnderweight → Equal-Weight$5 → $14+261.3%

Peers

Mkt cap
TickerCompanyMkt cap
VSTMVerastem Inc1.13B
RVMDRevolution Medicines Inc41.32B
BBOTBridgeBio Oncology Therapeutics Inc194.72M
ERASErasca Inc5.79B
TNGXTango Therapeutics Inc4.21B
ELTXElicio Therapeutics Inc46.14M
RCUSArcus Biosciences Inc2.70B
CRDFCardiff Oncology Inc60.60M
TOVXTheriva Biologics Inc7.05M
BLRXBioline Rx Ltd ADR8.09M

Insider trading

7 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Zeskind Benjamin J.PRESIDENT AND CEOJun 23 '26Buy4.562,40010,9482,315,252Jun 24 04:11 PM
Hall Brett MatthewCHIEF SCIENTIFIC OFFICERJun 15 '26Buy4.156,03525,045382,531Jun 16 04:15 PM
Brakewood Harold EugeneChief Business OfficerJan 16 '26Buy4.765,25024,99011,050Jan 21 09:09 AM
Schall Thomas J.DirectorJan 15 '26Buy4.6721,645101,04174,530Jan 20 09:17 AM
Hall Brett MatthewCHIEF SCIENTIFIC OFFICERJan 15 '26Buy4.572,29810,502376,496Jan 16 04:07 PM
Neufeld Leah RCHIEF PEOPLE OFFICERJan 13 '26Buy4.152,62610,90625,970Jan 15 08:06 AM
Feinberg PeterDirectorJan 12 '26Buy4.3520,00086,904135,441Jan 14 08:10 AM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWNiShares Russell 2000 Value ETFAUM: 14.10B
IBBiShares Biotechnology ETFAUM: 11.36B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
IWCiShares Micro-Cap ETFAUM: 1.22B
SBIOALPS Medical Breakthroughs ETFAUM: 192.65M
BUSMEA Bridgeway Ultra-Small Company Market ETFAUM: 111.21M
AVSCAvantis U.S Small Cap Equity ETFAUM: 3.23B

News

latest 14 of 206
  • Immuneering Appoints Accomplished Commercial Leader Grant Bogle to Board of Directors (GlobeNewswire)
  • Atebimetinib Combinations with Anti-PD1 Cured 50% of Mice in a RAS-Mutant Colorectal Cancer Model and Nearly Doubled Survival in a RAS-Mutant Lung Cancer Model; New Data Presented at SITC 2026 (GlobeNewswire) +9.20%
  • Immuneering to Present at the Guggenheim 3rd Annual Healthcare Innovation Conference (GlobeNewswire) -10.37%
  • Immuneering to Highlight Atebimetinib's Broad Potential for Combinations in Pancreatic and Anaplastic Thyroid Cancers at the 2026 EORTC-NCI-AACR Symposium (GlobeNewswire)
  • Immuneering Reports Third Quarter 2026 Financial Results and Provides Business Updates (GlobeNewswire) -6.84%
  • Loading…
  • Immuneering Presents Design and Methodology of Ongoing Phase 3 MAPKeeper 301 Trial at ESMO Congress 2026 (GlobeNewswire)
  • Immuneering to Present at the 41st Annual Meeting of the Society for Immunotherapy of Cancer (SITC) (GlobeNewswire)
  • Immuneering Presents Data at 2026 AACR Conference on Pancreatic Cancer Supporting Atebimetinib's Mechanisms Designed to Extend Survival in Pancreatic Cancer (GlobeNewswire)
  • Immuneering to Present at the ESMO Congress 2026 (GlobeNewswire)
  • Immuneering to Present at the AACR Conference on Pancreatic Cancer, Highlighting Atebimetinib's Dual Mechanism for Extended Survival (GlobeNewswire)
  • Immuneering to Participate in Upcoming Investor Conferences (GlobeNewswire)
  • Immuneering Comments on Today's FDA Approval in Second-Line Metastatic Pancreatic Cancer, Reiterates Focus on First-Line Patients (GlobeNewswire)
  • Zillow downgraded, Global Payments upgraded: Wall Street's top analyst calls (The Fly)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-10-29-0.370-0.305-0.2080.000.007
2026Q22026-08-06-0.270-0.269-0.2670.000.007
2026Q12026-05-15-0.210-0.252-0.2080.000.005
2025Q42026-03-06-0.180-0.312-0.1790.000.006
2025Q32025-11-12-0.380-0.388-0.3770.000.006
2025Q22025-08-13-0.400-0.400-0.4010.000.006
2025Q12025-05-05-0.420-0.527-0.4240.000.003
2024Q42025-03-20-0.580-0.416-0.5810.000.005
2024Q32024-11-13-0.490-0.552-0.4890.000.007
2024Q22024-08-06-0.470-0.520-0.4750.000.007
2024Q12024-05-07-0.490-0.503-0.4870.000.007
2023Q42024-03-01-0.520-0.463-0.5150.000.009
2023Q32023-11-09-0.430-0.489-0.4300.000.008
2023Q22023-08-03-0.430-0.528-0.4260.000.008
2023Q12023-05-04-0.510-0.541-0.5150.000.018
2022Q42023-03-06-0.500-0.561-0.5020.000.067

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2021FY-2.460-3.298-1.2742.082.44
2022FY-1.910-1.931-1.9140.320.45
2023FY-1.880-1.819-1.8820.000.00
2024FY-2.040-1.794-2.0360.000.00
2025FY-1.270-1.417-1.2730.000.00
2026FY--1.233--0.00
2027FY--1.614--0.00
2028FY--1.454--26.15
2029FY--1.009--74.78
2030FY--0.013--195.4

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-10-307000.000.000.00
2026Q4S2026-10-296000.000.000.00
2026Q4S2026-08-266000.000.000.00
2026Q4S2026-08-237000.000.000.00
2026Q4S2026-08-068000.000.000.00
2026Q4S2026-07-077000.000.000.00
2026Q4S2026-05-186000.000.000.00
2026Q4S2026-05-155000.000.000.00
2026Q4S2026-03-064000.000.000.00
2026Q4S2026-02-183000.000.000.00
2026Q4S2026-02-062000.000.000.00
2026Q4S2025-11-131000.000.000.00
2026Q4S2025-11-111000.000.000.00
2026Q4S2025-11-101000.000.000.00

Estimate history

EPS, annual-0.302-0.668-1.274-1.914-1.882-2.036-1.273-1.0282
Period2019202020212022202320242025TTM
EPS, quarterly-0.489-0.581-0.424-0.401-0.377-0.179-0.208-0.267-0.374
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual1.922.3122.080.3170000
Period2019202020212022202320242025TTM
Sales, quarterly000000000
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual25.51425.51426.3226.41929.27231.0564.64864.763
Period2019202020212022202320242025MRQ
Shares, quarterly31.0531.0535.98635.98763.48364.64864.68964.69764.763
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Total Revenue0.000.000.000.000.322.082.311.92
Cost of Goods Sold Incl. D&A0.730.700.710.760.951.181.301.23
Gross Profit-0.73-0.70-0.71-0.76-0.640.901.010.68
Selling, General and Administrative Excl. Other73.1558.6863.3657.6551.1134.7818.096.98
Research and Development54.3741.8147.7241.4036.1126.5114.984.27
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-73.88-59.38-64.07-58.41-51.74-33.89-17.08-6.29
Interest Expense0.000.000.000.000.000.00-0.35
Unusual Expense0.000.000.000.000.000.000.001.12
Net Income Before Taxes-66.50-56.02-61.04-53.47-50.51-33.84-17.04-7.71
Income Taxes0.000.000.000.000.00-0.310.000.00
Consolidated Net Income-66.50-56.02-61.04-53.47-50.51-33.54-17.04-7.71
Net Income From Continuing Operations-66.50-56.02-61.04-53.47-50.51-33.54-17.04-7.71
Net Income-66.50-56.02-61.04-53.47-50.51-33.54-17.04-7.71
EPS (Recurring)-1.03-1.27-2.04-1.88-1.91-1.27-0.67-0.27
EPS (Basic, Before Extraordinaries)-1.03-1.27-2.04-1.88-1.91-1.27-0.67-0.30
EPS (Diluted)-1.03-1.27-2.04-1.88-1.91-1.27-0.67-0.30
EBITDA-73.15-58.68-63.36-57.65-50.95-33.73-17.00-6.27
Non-Operating Income (Expense)7.373.353.034.941.230.040.040.06
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense6.966.316.505.734.061.321.090.60
Price To Sales Ratio----403.77204.62--
Gross Margin-----201.2843.1243.7535.67
Operating Margin-----16,325.77-1,629.17-739.01-327.71
Net Margin-----15,937.29-1,612.33-737.17-401.59
Shares Outstanding64.7664.6531.0529.2726.4226.3225.5125.51
Market Capitalization249.34249.3468.31215.13128.06419.46418.16-

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.190.190.180.170.090.090.180.17
Gross Profit-0.19-0.19-0.18-0.17-0.09-0.09-0.18-0.17
Selling, General and Administrative Excl. Other25.6018.8115.1513.5815.2914.6715.3118.38
Research and Development20.6613.9310.589.1910.8110.3911.4114.80
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-25.79-19.00-15.34-13.75-15.38-14.76-15.48-18.56
Interest Expense0.000.000.000.000.000.000.000.00
Unusual Expense0.000.000.000.000.000.000.000.00
Net Income Before Taxes-24.19-17.27-13.46-11.58-14.96-14.43-15.05-18.05
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-24.19-17.27-13.46-11.58-14.96-14.43-15.05-18.05
Net Income From Continuing Operations-24.19-17.27-13.46-11.58-14.96-14.43-15.05-18.05
Net Income-24.19-17.27-13.46-11.58-14.96-14.43-15.05-18.05
EPS (Recurring)-0.37-0.27-0.21-0.18-0.38-0.40-0.42-0.58
EPS (Basic, Before Extraordinaries)-0.37-0.27-0.21-0.18-0.38-0.40-0.42-0.58
EPS (Diluted)-0.37-0.27-0.21-0.18-0.38-0.40-0.42-0.58
EBITDA-25.60-18.81-15.15-13.58-15.29-14.67-15.31-18.38
Non-Operating Income (Expense)1.601.731.872.170.420.320.440.51
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense2.061.631.641.641.461.521.691.72
Shares Outstanding64.7664.7064.6964.6563.4835.9935.9931.05
Market Capitalization249.34322.84340.72424.87290.99121.2754.5568.31

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Cash & Short Term Investments172.8336.1485.67105.52149.2037.0913.78
Short Term Receivables0.000.000.000.010.250.500.21
Inventories0.000.000.000.000.000.000.00
Other Current Assets3.413.443.423.212.890.140.07
Total Current Assets176.2539.5989.08108.75152.3337.7314.06
Net Property, Plant & Equipment4.264.795.405.786.130.680.04
Total Investments and Advances44.180.000.000.001.000.000.00
Intangible Assets7.017.047.077.107.14-0.00
Deferred Tax Assets-----0.050.02
Other Assets0.281.301.030.740.100.010.00
Total Assets231.9952.71102.58122.37166.7038.4714.12
Short Term Debt Incl. Current Port. of LT Debt0.400.340.300.380.270.080.00
Accounts Payable1.541.962.113.151.391.480.29
Other Current Liabilities8.135.215.434.523.970.700.21
Total Current Liabilities10.077.507.858.055.632.260.51
Long Term Debt3.433.824.164.465.0958.6516.61
Provision for Risks Charges0.000.000.000.000.000.000.00
Deferred Tax Liabilities-----0.050.02
Other Liabilities0.000.000.000.000.000.003.51
Total Liabilities13.5011.3312.0112.5210.7260.9520.65
Non-Equity Reserves0.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.00
Common Equity218.4841.3990.58109.85155.98-22.48-6.53
Total Shareholders Equity218.4841.3990.58109.85155.98-22.48-6.53
Accumulated Minority Interest0.000.000.000.000.000.000.00
Total Equity218.4841.3990.58109.85155.98-22.48-6.53
Total Liabilities & Stockholders Equity231.9952.71102.58122.37166.7038.4714.12
Book Value Per Share3.381.333.094.165.93-0.88-0.26
Tangible Book Value Per Share3.271.112.853.895.65-0.88-0.26
Full-Time Employees3766687364--
Price to Book Ratio1.481.182.071.052.732.64-
Return on Assets-39.36-78.61-47.54-34.95-32.69-64.80-
Return on Equity-43.12-92.51-53.36-38.00-50.24--
Return on Invested Capital-25.25-135.00-56.44-44.19-20.82-47.11-76.46
Quick Ratio17.505.2811.3513.5027.0416.7327.83
Current Ratio17.505.2811.3513.5027.0416.7327.83

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Net Income-66.50-56.02-61.04-53.47-50.51-33.54-17.04-7.71
Depreciation0.980.700.710.760.800.160.080.02
Other Funds (Non Cash)5.216.166.254.713.901.931.092.76
Funds from Operations-60.31-49.17-54.07-47.99-45.82-31.75-15.87-4.94
Extraordinary Item0.000.000.000.000.000.000.000.00
Changes in Working Capital-1.253.82-0.93-0.971.720.901.250.44
Cash from Operating Activities-61.56-45.34-55.00-48.97-44.10-30.85-14.62-4.50
Capital Expenditures-0.25-0.14-0.08-0.34-0.74-0.06-0.05-0.02
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.070.000.00
Purchase or Sale of Investments-107.60-88.6026.527.6442.57-75.630.000.00
Purchase of Investments-172.77-88.60-5.41-44.66-50.10-75.630.000.00
Sale Or Maturity of Investments65.170.0031.9352.3092.680.000.000.00
Other Uses0.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.00
Cash from Investing Activities-107.84-88.7426.437.3041.83-75.62-0.05-0.02
Cash Dividends Paid0.000.000.000.000.000.000.000.00
Change in Capital Stock0.07226.585.3028.440.02144.2637.9817.23
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.00
Sale of Common Pref Stock0.07226.585.3028.440.02144.2637.9817.23
Proceedsfrom Stock Options-0.59225.794.2028.00-0.28142.9837.9817.23
Issuance or Reduction of Debt, Net0.000.000.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.00
Cash from Financing Activities0.07226.585.3028.440.02144.2637.9817.23
Net Change in Cash-169.3492.50-23.26-13.23-2.2537.8023.3112.71
Free Cash Flow-61.81-45.49-55.08-49.31-44.84-30.91-14.67-4.52
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.00-0.310.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments145.41149.90156.69172.83227.5626.36
Short Term Receivables0.000.000.000.000.000.00
Inventories0.000.000.000.000.000.00
Other Current Assets5.318.094.723.411.541.37
Total Current Assets150.71157.99161.41176.25229.1027.73
Net Property, Plant & Equipment3.854.024.174.264.304.46
Total Investments and Advances20.7132.7741.9544.180.000.00
Intangible Assets6.997.007.007.017.027.03
Other Assets0.300.280.280.280.630.84
Total Assets182.56202.06214.81231.99241.0640.06
Short Term Debt Incl. Current Port. of LT Debt0.450.430.410.400.380.37
Accounts Payable2.763.381.451.541.602.40
Other Current Liabilities7.594.313.118.137.564.72
Total Current Liabilities10.798.124.9710.079.557.49
Long Term Debt3.093.203.323.433.533.63
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.00
Total Liabilities13.8811.328.2913.5013.0811.12
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity168.68190.74206.52218.48227.9828.94
Total Shareholders Equity168.68190.74206.52218.48227.9828.94
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity168.68190.74206.52218.48227.9828.94
Total Liabilities & Stockholders Equity182.56202.06214.81231.99241.0640.06
Book Value Per Share2.602.953.193.383.590.80
Tangible Book Value Per Share2.502.843.083.273.480.61
Full-Time Employees655755375454
Price to Book Ratio1.481.561.561.838.712.90
Return on Assets-31.40-47.31-41.01-39.36-40.37-106.07
Return on Equity-33.53-52.15-43.84-43.12-43.75-130.47
Return on Invested Capital-14.08-8.91-6.41-5.22-6.46-44.32
Quick Ratio13.9719.4732.4517.5024.003.70
Current Ratio13.9719.4732.4517.5024.003.70

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-24.19-17.27-13.46-11.58-14.96-14.43
Depreciation0.190.190.180.430.090.01
Other Funds (Non Cash)1.701.051.231.231.541.69
Funds from Operations-22.30-16.04-12.05-9.92-13.34-12.73
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital5.52-0.47-6.380.081.363.29
Cash from Operating Activities-16.79-16.50-18.43-9.84-11.98-9.45
Capital Expenditures-0.02-0.03-0.08-0.12-0.01-0.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments33.4810.51-62.99-88.600.000.00
Purchase of Investments-0.19-11.99-71.99-88.600.000.00
Sale Or Maturity of Investments33.6722.509.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities33.4710.48-63.07-88.72-0.01-0.00
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.220.020.18-0.36213.19-0.06
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.220.020.18-0.36213.19-0.06
Proceedsfrom Stock Options0.000.000.00-0.59212.77-0.06
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities0.220.020.18-0.36213.19-0.06
Net Change in Cash16.90-6.00-81.32-98.92201.21-9.51
Free Cash Flow-16.80-16.53-18.51-9.96-11.98-9.45

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3026.21%14.6M55.7M709.60K
2026-10-1529.34%16.3M55.6M714.04K
2026-09-3027.85%15.5M55.6M732.47K
2026-09-1527.95%15.6M55.6M947.74K
2026-08-3126.67%14.8M55.6M1.21M
2026-08-1425.93%14.4M55.6M1.51M
2026-07-3127.69%15.4M55.6M1.50M
2026-07-1527.34%15.2M55.6M1.52M
2026-06-3026.91%15.0M55.9M1.47M
2026-06-1525.12%14.0M55.9M1.38M
2026-05-2922.78%12.7M55.9M1.14M
2026-05-1517.71%9.9M55.9M858.77K
2026-04-3018.14%9.5M52.4M909.11K
2026-04-1518.34%9.6M52.4M1.01M
2026-03-3119.67%10.3M52.4M1.64M
2026-03-1321.49%11.3M52.4M1.72M
2026-02-2721.17%11.1M52.3M1.69M
2026-02-1321.84%11.4M52.3M1.74M
2026-01-3023.09%11.3M48.8M1.82M
2026-01-1522.97%11.2M48.8M1.76M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.501.001.751.204.56715.000.000.895-0.0170.001
call5.000.000.100.101.6193260.000.198-0.0150.002
call7.500.000.050.052.5271610.000.081-0.0120.001
call10.000.000.750.103.37756.000.000.067-0.0150.001
put2.500.000.100.052.5552060.00-0.107-0.0150.001
put5.000.801.551.503.23580.000.00-0.800-0.0150.002
put7.503.004.204.105.5850.000.00-0.919-0.0120.001
put10.004.108.505.5014.54629.000.00-0.933-0.0140.001

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-094Statement of changes in beneficial ownership of securities2026-11-09SEC
2026-11-093Initial statement of beneficial ownership of securities2026-11-09SEC
2026-11-098-KCurrent report2026-11-09SEC
2026-10-2910-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-10-298-KCurrent report2026-10-29SEC
2026-08-0510-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-058-KCurrent report2026-08-05SEC
2026-07-28SCHEDULE 13GSEC
2026-07-174Statement of changes in beneficial ownership of securities2026-07-16SEC
2026-07-163Initial statement of beneficial ownership of securities2026-07-16SEC
2026-06-244Statement of changes in beneficial ownership of securities2026-06-23SEC
2026-06-164Statement of changes in beneficial ownership of securities2026-06-15SEC
2026-06-158-KCurrent report2026-06-11SEC
2026-06-114Statement of changes in beneficial ownership of securities2026-06-11SEC
2026-06-114Statement of changes in beneficial ownership of securities2026-06-11SEC
2026-06-114Statement of changes in beneficial ownership of securities2026-06-11SEC
2026-06-114Statement of changes in beneficial ownership of securities2026-06-11SEC
2026-06-114Statement of changes in beneficial ownership of securities2026-06-11SEC
2026-06-118-KCurrent report2026-06-11SEC
2026-06-018-KCurrent report2026-06-01SEC
2026-05-1510-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-158-KCurrent report2026-05-15SEC
2026-04-20DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-04-20DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-04-20SEC
2026-03-174Statement of changes in beneficial ownership of securities2026-03-13SEC
2026-03-0610-KAnnual report pursuant to Section 13 or 15(d)2025-12-31SEC
2026-03-068-KCurrent report2026-03-06SEC
2026-02-054Statement of changes in beneficial ownership of securities2026-02-03SEC
2026-02-054Statement of changes in beneficial ownership of securities2026-02-03SEC
2026-02-054Statement of changes in beneficial ownership of securities2026-02-03SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-0635.99K200
2026-050000
2026-040000
2026-030000
2026-020000
2026-01234.34K500
2025-120000
2025-110000

Institutional holders

Manager% owned
FMR LLC14.21%
BlackRock, Inc.6.76%
Sanofi4.19%
VANGUARD CAPITAL MANAGEMENT LLC3.53%
PRICE T ROWE ASSOCIATES INC /MD/2.99%
GEODE CAPITAL MANAGEMENT, LLC2.12%
STATE STREET CORP1.55%
Nuveen, LLC1.34%
DCF Advisers, LLC1.33%
Aberdeen Group plc1.21%

Funds

Fund% owned
Fidelity Growth Company Fund4.54%
VANGUARD TOTAL STOCK MARKET INDEX FUND2.51%
iShares Russell 2000 ETF2.11%
Select Biotechnology Portfolio1.69%
T. Rowe Price New Horizons Fund, Inc.1.40%
Fidelity Growth Company K6 Fund1.29%
Fidelity Series Growth Company Fund1.11%
VANGUARD EXTENDED MARKET INDEX FUND0.95%
Fidelity Small Cap Index Fund0.90%
iShares Russell 2000 Value ETF0.77%

OakChart. IMRX. Cached 15 minutes.